On February 27, 2025, Imunon, Inc. (IMNN) announced financial results for 2024 and provided a business update. The company is currently finishing preparations to conduct a Phase 3 clinical trial of its lead development compound, IMNN-001, in the treatment of advanced ovarian cancer. We anticipate the 500-patient trial will initiate before the end of the first quarter of 2025. The company is continuing to pursue all avenues for funding the trial and we continue to anticipate an update on its funding strategy in the near term. Imunon also recently announced immunogenicity data from the Phase 1 trial of IMNN-101, its investigational DNA plasmid vaccine. The Phase 1 study was conducted in 24 healthy volunteers as a seasonal COVID-19 vaccine. The results showed IMNN-101 was safe and well tolerated and generated a persistent 2- to 4-fold increase in serum neutralizing antibody titers. The company is continuing to seek potential partners for further development of IMNN-101.
